HealthModerna and Merck say mRNA cancer vaccine cut death or recurrence risk by 42%
Moderna and Merck said a late-stage trial found their personalized mRNA vaccine for melanoma reduced the risk of death or recurrence by 42% compared with standard treatment. The companies are in discussions with regulators about approval.
A
Ars Technica★★★☆☆2026-10-22 22:12Original
Moderna and Merck say mRNA cancer vaccine cut death or recurrence risk by 42%
Health